- Home
- All Stock List
- BSE
- Suven Pharmaceuticals Ltd Share Price
1,135.65
1.25 (0.11%)
-
Outperforms Index
69.63%
Return (1Y)
Beaten BSE Healthcare by 51.39%
-
More Volatile
2.56%
Standard Deviation (1Y)
Higher than BSE Healthcare by 1.49%
-
Consistent Performer
8/12
Months
beaten BSE Healthcare
-
AxisDirect View
No View
1,359
597
News & Announcements
-
Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation
26 - Apr - 2025 12:00 | 8 days ago
Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench.
In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions.
The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.
Powered by Capital Market - Live News
-
Suven Pharmaceuticals to table results
38 days ago
-
Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under:
Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications')
Short Term Rating - CRISIL A1+ (Reaffirmed)
Powered by Capital Market - Live News
-
Suven Pharmaceuticals to table results
38 days ago
-
Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under:
Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications')
Short Term Rating - CRISIL A1+ (Reaffirmed)
Powered by Capital Market - Live News
-
Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24.
Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24.
In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7%
In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules.
In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2.
On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A.
Vivek Sharma, executive chairman, commented, “Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.”
V. Prasada Raju, managing director, added: “We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.”
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.
Powered by Capital Market - Live News
-
Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation
26 - Apr - 2025 12:00 | 8 days ago
Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench.
In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions.
The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.
Powered by Capital Market - Live News
-
Suven Pharmaceuticals to table results
38 days ago
-
Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under:
Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications')
Short Term Rating - CRISIL A1+ (Reaffirmed)
Powered by Capital Market - Live News
-
Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24.
Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24.
In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7%
In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules.
In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2.
On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A.
Vivek Sharma, executive chairman, commented, “Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.”
V. Prasada Raju, managing director, added: “We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.”
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.
Powered by Capital Market - Live News
-
Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation
26 - Apr - 2025 12:00 | 8 days ago
Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench.
In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions.
The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.
Powered by Capital Market - Live News
-
Suven Pharmaceuticals to table results
38 days ago
-
Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under:
Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications')
Short Term Rating - CRISIL A1+ (Reaffirmed)
Powered by Capital Market - Live News
-
Suven Pharmaceuticals to table results
38 days ago
-
Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under:
Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications')
Short Term Rating - CRISIL A1+ (Reaffirmed)
Powered by Capital Market - Live News
-
Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24.
Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24.
In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7%
In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules.
In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2.
On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A.
Vivek Sharma, executive chairman, commented, “Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.”
V. Prasada Raju, managing director, added: “We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.”
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.
Powered by Capital Market - Live News
Stock Trivia
GovT shareholding in Suven Pharmaceuticals Ltd has increased by 16.95% since past 3 Months
GovT shareholding in Suven Pharmaceuticals Ltd has increased by 33.98% since past 1 Year
GovT shareholding in Suven Pharmaceuticals Ltd has increased by 16.95% since past 3 Months
FII shareholding in Suven Pharmaceuticals Ltd has increased by 15.78% since past 1 Year
MF shareholding in Suven Pharmaceuticals Ltd has decreased by -14.56% since past 1 Year
GovT shareholding in Suven Pharmaceuticals Ltd has increased by 33.98% since past 1 Year
GovT shareholding in Suven Pharmaceuticals Ltd has increased by 16.95% since past 3 Months
GovT shareholding in Suven Pharmaceuticals Ltd has increased by 33.98% since past 1 Year
